Nath Bio-Genes (India) Ltd

Nath Bio-Genes (India) Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will be shut from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the quarter and half-year ending September 30, 2026. The specific date for the board meeting to approve these results will be communicated separately.

Nath Bio-Genes (India) Ltd has announced the record date for its 33rd Annual General Meeting (AGM) and dividend eligibility. The AGM will be held on Thursday, September 24, 2026, via Video Conferencing/Other Audio Visual Means. The record date for determining shareholder eligibility for voting at the AGM and for dividend payout is set for Friday, September 11, 2026. This announcement is made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Nath Bio-Genes (India) Ltd has announced the record date for its 33rd Annual General Meeting (AGM) and dividend eligibility. The AGM will be held on Thursday, September 24, 2026, via Video Conferencing/Other Audio Visual Means (VC/OAVM). The cut-off date for determining eligibility to vote at the AGM and for dividend entitlement is Friday, September 11, 2026. This intimation is made pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Nath Bio-Genes (India) Ltd has announced its 33rd Annual General Meeting (AGM) will be held on Thursday, September 24, 2026, at 11:00 a.m. IST. The meeting will be conducted through Video Conferencing/Other Audio Visual Means (VC/OAVM). Shareholders will receive the integrated annual report for the financial year 2025-26 electronically. The company is providing a remote e-voting facility from September 21 to September 23, 2026, managed by NSDL. Voting rights are based on shares held as of the cut-off date, September 11, 2026. The agenda includes adopting financial statements, declaring a dividend of ₹2 per equity share, and re-appointing Mrs. Jeevanlata Kagliwal as a director.

Nath Bio-Genes (India) Ltd has announced the record date for its 33rd Annual General Meeting (AGM) and dividend. The AGM will be held on Thursday, September 24, 2026, via Video Conferencing/Other Audio Visual Means (VC/OAVM). The cut-off date for determining member eligibility to vote at the AGM is Friday, September 11, 2026. This announcement serves as a formal record for the company and its stakeholders.

Nath Bio-Genes (India) Ltd has announced its 33rd Annual General Meeting (AGM) to be held on Thursday, September 24, 2026, at 11:00 a.m. IST via Video Conferencing/Other Audio Visual Means (VC/OAVM). The company will present its audited financial statements for the fiscal year 2025-26, including the Balance Sheet and Profit & Loss Statement, along with the Directors' and Auditors' reports. A key agenda item is the declaration of a final dividend of ₹2 per equity share of face value ₹10 for FY 2025-26. Shareholders will also vote on the re-appointment of Mrs. Jeevanlata Kagliwal as a director. The company is providing remote e-voting facilities from September 21 to September 23, 2026, with a cut-off date of September 11, 2026, for determining voting rights.

Nath Bio-Genes (India) Ltd has received a communication from SEBI appointing CNK & Associates LLP as a Forensic Auditor. The audit will cover the company's books of account and records for the financial years 2020-21 to 2025-26. The company has stated it will extend full cooperation to the auditor and is committed to corporate governance and regulatory compliance. The specific matters to be examined by the forensic auditor were specified by SEBI in its communication.

Nath Bio-Genes (India) Ltd. announced its unaudited standalone financial results for the quarter ended June 30, 2026. The company's Board of Directors approved these results in a meeting held on July 29, 2026. Additionally, the Board approved the date for the 33rd Annual General Meeting to be held on September 24, 2026, via video conference. The financial results include statements for both standalone and consolidated unaudited financial results for the specified quarter, along with the statutory auditors' limited review reports.

Nath Bio-Genes (India) Ltd has announced that its Board of Directors will convene on July 29, 2026. The primary agenda item is to consider, approve, and take on record the unaudited financial results, both standalone and consolidated, for the quarter ended June 30, 2026. The company has also closed its trading window from June 30, 2026, and it will reopen on August 1, 2026, 48 hours after the declaration of these financial results, in compliance with insider trading regulations.

Nath Bio-Genes (India) Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from July 1, 2026, until 48 hours after the declaration of the Unaudited Financial Results for the quarter ending June 30, 2026. The specific date for the board meeting to approve these results will be communicated separately. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.